Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.44

-2.7%

11:15 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (10162)	1/27/2004 1:40:53 PM
From: Icebrg	Read Replies (1) of 52153

CTIC >> Primarily as a salvage type of therapy for multiple myeloma>> Not quite correct according to today's presentation at Piper's. 2003 figures. APL 13 % (approved indication) MDS 53 % Myeloma 29 % Other uses 5 % Sales target for 2004 is 35 mUSD. Last year they should have made about 24 mUSD. There was a slow-down last year in sales to myeloma patients as Velcade was approved. But Bianco claims that during the last quarter the sales to this group of patients has picked up again. As myeloma "in principle" is un-curable, patients will eventually come back after the relapse from their treatment with Velcade, I guess. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next